

^bMedically able to tolerate major abdominal surgery.

^dSurgery as primary therapy is appropriate for T1 cancer or actively bleeding cancer, or when postoperative adjuvant therapy is preferred.

^eSee Principles of Surgery (GAST-A).

^fSee Principles of Systemic Therapy (GAST-B).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 1.2007, 05/09/07 © 2007 National Comprehensive Cancer Network, Inc. All rights reserved. These guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.


GAST-2



National
Comprehensive
Cancer
Network[®]

NCCN Guidelines Version 2.2022 Gastric Cancer

[NCCN Guidelines Index](#)
[Table of Contents](#)
[Discussion](#)



^a See Principles of Endoscopic Staging and Therapy (GAST-A).

^d See Principles of Pathologic Review and Biomarker Testing (GAST-B).

^f See Principles of Surgery (GAST-C).

^j See Staging (ST-1) for tumor classification.

^k Medically able to tolerate major surgery.

¹ Medically unable to tolerate major surgery or medically fit patients who decline surgery.

ⁿ Surgery as primary therapy is appropriate for cT1b cancer or actively bleeding cancer, or when postoperative therapy is preferred.

^o See Principles of Systemic Therapy (GAST-E).

^p See Principles of Radiation Therapy (GAST-G).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Version 2.2022, 01/19/22 © 2022 National Comprehensive Cancer Network (NCCN), All rights reserved. NCCN guidelines and this illustration may not be reproduced in any form without the express written permission of NCCN.

GAST-2

